|
EP1539228B1
(en)
|
2002-09-11 |
2010-12-29 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
|
EP2279412B1
(en)
|
2008-04-09 |
2017-07-26 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
|
WO2009143167A2
(en)
|
2008-05-19 |
2009-11-26 |
Advaxis |
Dual delivery system for heterologous antigens
|
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
|
KR20250091300A
(ko)
|
2008-12-09 |
2025-06-20 |
제넨테크, 인크. |
항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
|
|
AU2010232347A1
(en)
|
2009-03-30 |
2011-09-29 |
Eisai R&D Management Co., Ltd. |
Liposome composition
|
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
|
JP5981436B2
(ja)
|
2010-10-01 |
2016-08-31 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
|
|
AU2012229218B2
(en)
|
2011-03-11 |
2017-03-02 |
Advaxis, Inc. |
Listeria-based adjuvants
|
|
CA2830822C
(en)
|
2011-04-01 |
2018-10-02 |
Curis, Inc. |
A thienopyrimidine phosphoinositide 3-kinase inhibitor with a zinc binding moiety
|
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
AR087405A1
(es)
|
2011-08-01 |
2014-03-19 |
Genentech Inc |
Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
|
|
CA2862390A1
(en)
|
2012-01-25 |
2013-08-01 |
Dnatrix, Inc. |
Biomarkers and combination therapies using oncolytic virus and immunomodulation
|
|
AU2013232291B8
(en)
|
2012-03-12 |
2016-07-21 |
Advaxis, Inc. |
Suppressor cell function inhibition following listeria vaccine treatment
|
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
SG11201507477XA
(en)
*
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
KR102389677B1
(ko)
*
|
2013-03-15 |
2022-04-21 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
|
CN105073128A
(zh)
*
|
2013-04-03 |
2015-11-18 |
Ibc药品公司 |
用于诱导对疾病的免疫应答的组合疗法
|
|
WO2014193898A1
(en)
*
|
2013-05-31 |
2014-12-04 |
Merck Sharp & Dohme Corp. |
Combination therapies for cancer
|
|
BR112015028326A8
(pt)
|
2013-06-03 |
2018-01-23 |
Novartis Ag |
combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica
|
|
WO2014204856A1
(en)
*
|
2013-06-17 |
2014-12-24 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid anticancer derivatives and their uses
|
|
MY183503A
(en)
*
|
2013-07-16 |
2021-02-23 |
Genentech Inc |
Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
|
AR097279A1
(es)
|
2013-08-09 |
2016-03-02 |
Actelion Pharmaceuticals Ltd |
Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
EP3035964B1
(en)
*
|
2013-08-20 |
2020-09-23 |
Merck Sharp & Dohme Corp. |
Treating cancer with a combination of a pd-1 antagonist and dinaciclib
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
HRP20221262T1
(hr)
*
|
2013-09-13 |
2022-12-09 |
Beigene Switzerland Gmbh |
Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
PT3049441T
(pt)
*
|
2013-09-27 |
2020-01-21 |
Hoffmann La Roche |
Formulações de anticorpos anti-pdl1
|
|
EP3470081A1
(en)
|
2013-10-01 |
2019-04-17 |
Mayo Foundation for Medical Education and Research |
Methods for treating cancer in patients with elevated levels of bim
|
|
US10241115B2
(en)
|
2013-12-10 |
2019-03-26 |
Merck Sharp & Dohme Corp. |
Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
|
|
SI3081576T1
(sl)
|
2013-12-12 |
2019-12-31 |
Shanghai Hengrui Pharmaceutical Co., Ltd., |
Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
|
|
EP3084003A4
(en)
|
2013-12-17 |
2017-07-19 |
Merck Sharp & Dohme Corp. |
Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
|
|
EP3083690A1
(en)
*
|
2013-12-17 |
2016-10-26 |
F.Hoffmann-La Roche Ag |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
|
EP3647324A1
(en)
*
|
2013-12-17 |
2020-05-06 |
F. Hoffmann-La Roche AG |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
US20150190506A1
(en)
*
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
CN105899537A
(zh)
|
2014-01-10 |
2016-08-24 |
博笛生物科技（北京）有限公司 |
靶向表达egfr的肿瘤的化合物和组合物
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
MX390904B
(es)
|
2014-02-04 |
2025-03-21 |
Incyte Corp |
Combinación de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cáncer.
|
|
US10570202B2
(en)
|
2014-02-04 |
2020-02-25 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
|
|
WO2015119923A1
(en)
|
2014-02-04 |
2015-08-13 |
Pfizer Inc. |
Combination of a pd-1 antagonist and a 4-abb agonist for treating cancer
|
|
SG10202108879SA
(en)
*
|
2014-02-10 |
2021-09-29 |
Merck Patent Gmbh |
TARGETED TGFβ INHIBITION
|
|
KR20240110004A
(ko)
|
2014-03-14 |
2024-07-12 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
WO2015148683A1
(en)
|
2014-03-26 |
2015-10-01 |
Tocagen Inc. |
A retroviral vector having immune-stimulating activity
|
|
AU2015241038A1
(en)
|
2014-03-31 |
2016-10-13 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
WO2015181624A2
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals, Inc |
Nucleoside derivatives for the treatment of cancer
|
|
ES2901705T3
(es)
|
2014-06-06 |
2022-03-23 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
|
|
CN110156892B
(zh)
|
2014-07-03 |
2023-05-16 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
EP4001311B1
(en)
|
2014-07-09 |
2025-11-05 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1/pd-1 combinations for treating tumors
|
|
BR112017000497B1
(pt)
|
2014-07-11 |
2023-12-26 |
Ventana Medical Systems, Inc |
Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
|
|
SG10202007111TA
(en)
*
|
2014-07-15 |
2020-09-29 |
Genentech Inc |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
MX2017000857A
(es)
|
2014-07-18 |
2017-10-11 |
Advaxis Inc |
Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata.
|
|
KR102524920B1
(ko)
|
2014-07-22 |
2023-04-25 |
아폴로믹스 인코포레이티드 |
항-pd-1 항체
|
|
EP3171896A4
(en)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
DK3177644T3
(da)
|
2014-08-05 |
2021-01-11 |
MabQuest SA |
Immunologiske reagenser, som binder til PD-1
|
|
ES2987034T3
(es)
|
2014-08-05 |
2024-11-13 |
Apollomics Inc |
Anticuerpos anti-PD-L1
|
|
US10800830B2
(en)
*
|
2014-08-08 |
2020-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity PD-1 agents and methods of use
|
|
US11149090B2
(en)
|
2014-08-12 |
2021-10-19 |
Alligator Bioscience Ab |
Combination therapies with anti CD40 antibodies
|
|
EP3070102A1
(en)
*
|
2015-03-18 |
2016-09-21 |
F. Hoffmann-La Roche AG |
Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies
|
|
WO2016023875A1
(en)
*
|
2014-08-14 |
2016-02-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
|
|
EP3185866A1
(en)
|
2014-08-25 |
2017-07-05 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
|
KR102329681B1
(ko)
|
2014-08-28 |
2021-11-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
고순도의 퀴놀린 유도체 및 이를 제조하는 방법
|
|
WO2016033555A1
(en)
|
2014-08-28 |
2016-03-03 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
|
CN112546238A
(zh)
*
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
US9535074B2
(en)
|
2014-09-08 |
2017-01-03 |
Merck Sharp & Dohme Corp. |
Immunoassay for soluble PD-L1
|
|
ES2771926T3
(es)
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
|
CN106687135A
(zh)
*
|
2014-09-15 |
2017-05-17 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和il‑17结合拮抗剂治疗癌症的方法
|
|
HRP20201656T1
(hr)
|
2014-09-16 |
2021-03-05 |
Innate Pharma |
Neutralizacija inhibitornih putova u limfocitima
|
|
JP2017535528A
(ja)
|
2014-10-03 |
2017-11-30 |
ノバルティス アーゲー |
組み合わせ治療
|
|
CN106852149B
(zh)
|
2014-10-10 |
2021-08-27 |
依奈特制药公司 |
Cd73阻断
|
|
MX391478B
(es)
|
2014-10-10 |
2025-03-21 |
Idera Pharmaceuticals Inc |
Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cáncer.
|
|
CN108064282A
(zh)
|
2014-10-14 |
2018-05-22 |
哈洛齐梅公司 |
腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
|
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
|
KR20170096112A
(ko)
*
|
2014-11-17 |
2017-08-23 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
|
SG11201704056XA
(en)
*
|
2014-11-20 |
2017-06-29 |
Hoffmann La Roche |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
|
CN105669862A
(zh)
*
|
2014-11-21 |
2016-06-15 |
上海中信国健药业股份有限公司 |
抗人pd-l1/kir双特异性抗体及其制备方法和应用
|
|
MX2017007321A
(es)
*
|
2014-12-02 |
2017-08-25 |
Celgene Corp |
Terapias de combinacion.
|
|
US10086000B2
(en)
|
2014-12-05 |
2018-10-02 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
|
WO2016089797A1
(en)
|
2014-12-05 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
|
WO2016090300A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
|
US10508108B2
(en)
|
2014-12-05 |
2019-12-17 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
|
RU2017123117A
(ru)
|
2014-12-09 |
2019-01-10 |
Мерк Шарп И Доум Корп. |
Система и способы получения биомаркеров генных сигнатур ответа на антагонисты pd-1
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
WO2016106160A1
(en)
*
|
2014-12-22 |
2016-06-30 |
Enumeral Biomedical Holdings, Inc. |
Methods for screening therapeutic compounds
|
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
|
JP2016155776A
(ja)
*
|
2015-02-24 |
2016-09-01 |
学校法人兵庫医科大学 |
抗腫瘍効果増強剤および抗腫瘍剤
|
|
KR20250024102A
(ko)
|
2015-02-25 |
2025-02-18 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 고미 억제 방법
|
|
CN112263677A
(zh)
|
2015-02-26 |
2021-01-26 |
默克专利股份公司 |
用于治疗癌症的pd-1/pd-l1抑制剂
|
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
|
KR20170122810A
(ko)
|
2015-03-04 |
2017-11-06 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
|
|
SG11201707383PA
(en)
|
2015-03-13 |
2017-10-30 |
Cytomx Therapeutics Inc |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
EP3839510A3
(en)
|
2015-04-17 |
2021-08-25 |
Merck Sharp & Dohme Corp. |
Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
|
|
DK3285809T3
(da)
*
|
2015-04-20 |
2019-11-18 |
Effector Therapeutics Inc |
Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
|
|
WO2016179576A1
(en)
*
|
2015-05-07 |
2016-11-10 |
Bioxcel Corporation |
Novel immunomodulatory therapeutic strategies targeting tumors in cancer
|
|
JP7028765B2
(ja)
*
|
2015-05-22 |
2022-03-02 |
トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー |
ベンズアミドおよび活性化合物組成物および使用方法
|
|
HK1252245A1
(zh)
|
2015-05-27 |
2019-05-24 |
Idenix Pharmaceuticals Llc |
用於治疗癌症的核苷酸
|
|
ES2810700T3
(es)
*
|
2015-05-29 |
2021-03-09 |
Hoffmann La Roche |
Metilación del promotor de PD-L1 en cáncer
|
|
CA2986126A1
(en)
*
|
2015-05-29 |
2016-12-08 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
|
|
EP3303373B1
(en)
|
2015-05-30 |
2020-04-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
US20180153884A1
(en)
*
|
2015-05-31 |
2018-06-07 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
|
MX390878B
(es)
|
2015-06-16 |
2025-03-21 |
Merck Patent Gmbh |
Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
|
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
|
ES2886107T3
(es)
|
2015-06-16 |
2021-12-16 |
Prism Biolab Co Ltd |
Antineoplásico
|
|
JP6896650B2
(ja)
*
|
2015-06-17 |
2021-06-30 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
US10007766B2
(en)
|
2015-07-13 |
2018-06-26 |
Biodesix, Inc. |
Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
CN116196426A
(zh)
|
2015-07-16 |
2023-06-02 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
|
RU2711380C2
(ru)
|
2015-07-16 |
2020-01-16 |
Байоксэл Терапьютикс, Инк. |
Новый подход к лечению рака с применением иммуномодуляции
|
|
WO2017019894A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
WO2017024465A1
(en)
*
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
BR112018002757A8
(pt)
|
2015-08-13 |
2023-04-11 |
Merck Sharp & Dohme |
Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio
|
|
SG11201801083UA
(en)
|
2015-08-20 |
2018-03-28 |
Eisai R&D Man Co Ltd |
Tumor therapeutic agent
|
|
CA2996685A1
(en)
|
2015-09-03 |
2017-03-09 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
SMT202500003T1
(it)
|
2015-09-25 |
2025-03-12 |
Hoffmann La Roche |
Anticorpi anti-tigit e procedimenti di utilizzo
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
CN108602887B
(zh)
|
2015-10-02 |
2022-06-21 |
豪夫迈·罗氏有限公司 |
对共刺激性tnf受体特异性的双特异性抗体
|
|
KR20250079249A
(ko)
*
|
2015-10-08 |
2025-06-04 |
마크로제닉스, 인크. |
암 치료를 위한 조합 치료법
|
|
US11130817B2
(en)
|
2015-10-12 |
2021-09-28 |
Innate Pharma |
CD73 blocking agents
|
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
|
JP6936221B2
(ja)
|
2015-11-02 |
2021-09-15 |
ファイブ プライム セラピューティクス， インコーポレイテッド |
Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
|
|
HRP20220436T1
(hr)
|
2015-11-03 |
2022-05-27 |
Janssen Biotech, Inc. |
Protutijela koja se specifično vežu na pd-1 i njihove uporabe
|
|
JP6411676B2
(ja)
|
2015-12-03 |
2018-10-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
EP3389783B1
(en)
|
2015-12-15 |
2024-07-03 |
Merck Sharp & Dohme LLC |
Novel compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
GB201522311D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
|
CA3007671A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
GB201522309D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
|
HUE063377T2
(hu)
|
2015-12-22 |
2024-01-28 |
Regeneron Pharma |
Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN108368179B
(zh)
*
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
|
LT3405495T
(lt)
|
2016-01-21 |
2021-08-10 |
Innate Pharma |
Inhibitorių kelių neutralizavimas limfocituose
|
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
|
DK3964529T3
(da)
|
2016-01-22 |
2025-06-30 |
MabQuest SA |
Ikke-blokerende pd1-specifikke antistoffer
|
|
US11710539B2
(en)
|
2016-02-01 |
2023-07-25 |
Biodesix, Inc. |
Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
|
|
JP7270379B2
(ja)
|
2016-03-08 |
2023-05-10 |
イナート・ファルマ・ソシエテ・アノニム |
Ｓｉｇｌｅｃ中和抗体
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
MX2018010546A
(es)
*
|
2016-03-15 |
2019-02-20 |
Chugai Pharmaceutical Co Ltd |
Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
|
|
US10947317B2
(en)
|
2016-03-15 |
2021-03-16 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
|
US11760803B2
(en)
|
2016-03-24 |
2023-09-19 |
Takeda Pharmaceutical Company Limited |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
WO2017165742A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
|
|
EP3436829A1
(en)
|
2016-03-30 |
2019-02-06 |
Centre Léon-Bérard |
Lymphocytes expressing cd73 in cancerous patient dictates therapy
|
|
RU2018137389A
(ru)
|
2016-04-07 |
2020-05-12 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Гетероциклические амиды, полезные в качестве модуляторов
|
|
ES2921855T3
(es)
|
2016-04-07 |
2022-09-01 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas útiles como moduladores de proteínas
|
|
WO2017180385A1
(en)
|
2016-04-12 |
2017-10-19 |
Eli Lilly And Company |
Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
|
|
JP2019515670A
(ja)
|
2016-04-15 |
2019-06-13 |
ジェネンテック， インコーポレイテッド |
がんをモニタリングし治療するための方法
|
|
US20200325234A1
(en)
*
|
2016-04-27 |
2020-10-15 |
Miradx |
Immune-based treatment of kras-variant cancer patients
|
|
EP3449921B1
(en)
|
2016-04-28 |
2023-05-31 |
Eisai R&D Management Co., Ltd. |
Eribulin for inhibiting tumor growth
|
|
WO2017192874A1
(en)
|
2016-05-04 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
|
WO2017191545A1
(en)
|
2016-05-05 |
2017-11-09 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
TW202408578A
(zh)
|
2016-05-13 |
2024-03-01 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
JP7194022B2
(ja)
*
|
2016-05-20 |
2022-12-21 |
イーライ リリー アンド カンパニー |
Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
|
|
RU2018145734A
(ru)
|
2016-06-08 |
2020-07-14 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Химические соединения в качестве ингибиторов atf4 пути
|
|
CN109563034A
(zh)
|
2016-06-08 |
2019-04-02 |
葛兰素史密斯克莱知识产权发展有限公司 |
化学化合物
|
|
NZ749997A
(en)
|
2016-07-05 |
2022-11-25 |
Beigene Ltd |
Combination of a pd-l antagonist and a raf inhibitor for treating cancer
|
|
WO2018015879A1
(en)
|
2016-07-20 |
2018-01-25 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
WO2018029124A1
(en)
*
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
TWI739887B
(zh)
|
2016-08-19 |
2021-09-21 |
英屬開曼群島商百濟神州有限公司 |
使用包含btk抑制劑的組合產品治療癌症
|
|
JP7138094B2
(ja)
|
2016-08-25 |
2022-09-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
|
|
BR112019005815A2
(pt)
*
|
2016-09-29 |
2019-06-25 |
Genentech Inc |
métodos de tratamento de um indivíduo com câncer de mama, kit para o tratamento de câncer de mama e combinação de fármacos para terapia de câncer de mama
|
|
EP3523287B1
(en)
|
2016-10-04 |
2021-09-01 |
Merck Sharp & Dohme Corp. |
Benzo[b]thiophene compounds as sting agonists
|
|
BR112019006504A2
(pt)
|
2016-10-06 |
2019-06-25 |
Pfizer Inc. |
regime de dosagem de avelumabe para o tratamento de câncer
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
MX2019003994A
(es)
|
2016-10-14 |
2019-09-19 |
Merck Sharp & Dohme |
Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
|
|
CA3041684C
(en)
*
|
2016-11-01 |
2023-09-26 |
Anaptysbio, Inc. |
Antibodies directed against programmed death- 1 (pd-1)
|
|
EP3535295A1
(en)
|
2016-11-02 |
2019-09-11 |
EngMab Sàrl |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
|
WO2018089293A2
(en)
|
2016-11-08 |
2018-05-17 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-pd1 and anti-ctla4 antibodies
|
|
US20190365788A1
(en)
|
2016-11-21 |
2019-12-05 |
Idenix Pharmaceuticals Llc |
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
WO2018102536A1
(en)
|
2016-11-30 |
2018-06-07 |
Oncomed Pharmaceuticals, Inc. |
Methods for treatment of cancer comprising tigit-binding agents
|
|
CN110234342A
(zh)
|
2016-12-01 |
2019-09-13 |
葛兰素史密斯克莱知识产权发展有限公司 |
组合疗法
|
|
US20190343803A1
(en)
|
2016-12-01 |
2019-11-14 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
JP2020511408A
(ja)
*
|
2016-12-12 |
2020-04-16 |
ジェネンテック， インコーポレイテッド |
抗ｐｄ−ｌ１抗体及び抗アンドロゲン薬を使用してがんを治療する方法
|
|
EP3558360A1
(en)
|
2016-12-22 |
2019-10-30 |
F. Hoffmann-La Roche AG |
Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
|
|
CN108239149B
(zh)
*
|
2016-12-25 |
2021-03-05 |
南京传奇生物科技有限公司 |
高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
|
|
AU2018205730B2
(en)
|
2017-01-05 |
2024-05-30 |
Centre Leon Berard |
Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
|
|
WO2018129301A1
(en)
|
2017-01-05 |
2018-07-12 |
Biodesix, Inc. |
Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
|
|
DK3565844T5
(da)
|
2017-01-09 |
2024-09-02 |
Tesaro Inc |
Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
WO2018138684A1
(en)
|
2017-01-27 |
2018-08-02 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
CN110234403A
(zh)
|
2017-01-27 |
2019-09-13 |
詹森生物科技公司 |
作为sting激动剂的环状二核苷酸
|
|
WO2018141959A1
(en)
|
2017-02-06 |
2018-08-09 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
IL308805B1
(en)
|
2017-02-21 |
2025-08-01 |
Regeneron Pharma |
Anti-pd-1 antibodies for treatment of lung cancer
|
|
CN108503691B
(zh)
*
|
2017-02-25 |
2021-07-23 |
复旦大学 |
一种人pd-l1蛋白高亲和性肽及其应用
|
|
JP2020509009A
(ja)
|
2017-02-27 |
2020-03-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
キナーゼ阻害剤としての複素環式アミド
|
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
WO2018167778A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of diagnosing and prognosing cancer
|
|
MX2019010848A
(es)
|
2017-03-16 |
2019-10-30 |
Innate Pharma |
Composiciones y procedimientos para el tratamiento del cancer.
|
|
EP3600410A1
(en)
|
2017-03-30 |
2020-02-05 |
Merck Patent GmbH |
Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
ES2899616T3
(es)
|
2017-04-28 |
2022-03-14 |
Five Prime Therapeutics Inc |
Polipéptidos del dominio extracelular del CD80 para su uso en aumentar los linfocitos T de memoria central
|
|
EP3621624B1
(en)
|
2017-05-12 |
2023-08-30 |
Merck Sharp & Dohme LLC |
Cyclic di-nucleotide compounds as sting agonists
|
|
US11685787B2
(en)
|
2017-05-16 |
2023-06-27 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-GITR agonist antibodies
|
|
US20200197384A1
(en)
|
2017-05-16 |
2020-06-25 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
JP2020522486A
(ja)
|
2017-06-01 |
2020-07-30 |
サイトメックス セラピューティクス インコーポレイテッド |
活性化可能抗ｐｄｌ１抗体、およびその使用方法
|
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
CA3066048A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
JP7657023B2
(ja)
|
2017-06-09 |
2025-04-04 |
プロビデンス ヘルス アンド サービシーズ－オレゴン |
がんの処置のための腫瘍反応性ヒトｔ細胞の同定のためのｃｄ３９およびｃｄ１０３の使用
|
|
CA3067268A1
(en)
|
2017-06-23 |
2018-12-27 |
Birdie Biopharmaceuticals, Inc. |
Crystalline resiquimod monosulfate anhydrate and its preparation and uses
|
|
TWI877099B
(zh)
|
2017-06-26 |
2025-03-21 |
英屬開曼群島商百濟神州有限公司 |
抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途
|
|
US20210145771A1
(en)
|
2017-07-03 |
2021-05-20 |
Glaxosmithkline Intellectual Property Development Limited |
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
|
JP2020525512A
(ja)
|
2017-07-03 |
2020-08-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物
|
|
AU2018298676A1
(en)
|
2017-07-10 |
2019-12-19 |
Innate Pharma |
Siglec-9-neutralizing antibodies
|
|
EP3655542A1
(en)
|
2017-07-18 |
2020-05-27 |
Institut Gustave Roussy |
Method for assessing the response to pd-1/pdl-1 targeting drugs
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
EP3661498A4
(en)
|
2017-08-04 |
2021-04-21 |
Merck Sharp & Dohme Corp. |
BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
|
|
RU2020109328A
(ru)
|
2017-08-04 |
2021-09-06 |
Мерк Шарп И Доум Корп. |
Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
|
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
US11377440B2
(en)
|
2017-10-05 |
2022-07-05 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING)
|
|
US20210238172A1
(en)
|
2017-10-05 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators and methods of using the same
|
|
WO2019068907A1
(en)
|
2017-10-06 |
2019-04-11 |
Innate Pharma |
RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73
|
|
CN109663130B
(zh)
*
|
2017-10-13 |
2021-06-29 |
江苏恒瑞医药股份有限公司 |
Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
|
|
AU2018353432A1
(en)
|
2017-10-19 |
2020-04-23 |
Debiopharm International S.A. |
Combination product for the treatment of cancer
|
|
WO2019089412A1
(en)
|
2017-11-01 |
2019-05-09 |
Merck Sharp & Dohme Corp. |
Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
MA50564A
(fr)
|
2017-11-06 |
2020-09-16 |
Hutchinson Fred Cancer Res |
Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
|
|
AR113878A1
(es)
|
2017-11-14 |
2020-06-24 |
Merck Sharp & Dohme |
Compuestos de biarilo sustituido como inhibidores de indolamina 2,3-dioxigenasa (ido)
|
|
EP3709986B1
(en)
|
2017-11-14 |
2023-11-01 |
Merck Sharp & Dohme LLC |
Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
|
CN108165536A
(zh)
*
|
2017-12-11 |
2018-06-15 |
浙江大学 |
一种重组溶瘤痘苗病毒及其制备方法与应用
|
|
US20210009630A1
(en)
|
2017-12-15 |
2021-01-14 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
US11685761B2
(en)
|
2017-12-20 |
2023-06-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
TW201929908A
(zh)
|
2017-12-21 |
2019-08-01 |
美商梅爾莎納醫療公司 |
吡咯并苯并二氮呯抗體共軛物
|
|
CN117050184A
(zh)
|
2017-12-28 |
2023-11-14 |
南京传奇生物科技有限公司 |
针对tigit的单域抗体和其变体
|
|
JP2021516215A
(ja)
*
|
2018-01-10 |
2021-07-01 |
アレイ・バイオファーマ・インコーポレーテッド |
癌を処置するための方法および併用療法
|
|
KR20250114571A
(ko)
|
2018-01-15 |
2025-07-29 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-1에 대한 단일-도메인 항체 및 이의 변이체
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019152743A1
(en)
|
2018-01-31 |
2019-08-08 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
WO2019177873A1
(en)
|
2018-03-13 |
2019-09-19 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
RU2020133020A
(ru)
|
2018-03-14 |
2022-04-14 |
Мерк Патент Гмбх |
Соединения и их применения для лечения опухолей у субъекта
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
US12094587B2
(en)
|
2018-03-29 |
2024-09-17 |
Biodesix, Inc. |
Apparatus and method for identification of primary immune resistance in cancer patients
|
|
US11702430B2
(en)
|
2018-04-03 |
2023-07-18 |
Merck Sharp & Dohme Llc |
Aza-benzothiophene compounds as STING agonists
|
|
EP3774764A1
(en)
|
2018-04-03 |
2021-02-17 |
Merck Sharp&Dohme Corp. |
Benzothiophenes and related compounds as sting agonists
|
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
|
EP3781687A4
(en)
|
2018-04-20 |
2022-02-09 |
Merck Sharp & Dohme Corp. |
NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
|
|
KR20210006353A
(ko)
|
2018-05-04 |
2021-01-18 |
톨리스 |
상피 세포 및 골수 세포 모두를 활성화시키는 tlr3 리간드
|
|
KR20210006405A
(ko)
|
2018-05-04 |
2021-01-18 |
메르크 파텐트 게엠베하 |
암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
|
|
EA202092136A1
(ru)
*
|
2018-05-07 |
2021-03-22 |
Генмаб А/С |
Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства
|
|
IL278522B2
(en)
|
2018-05-07 |
2025-10-01 |
Genmab As |
Methods for treating cancer with a combination of anti-PD-1 antibody and always an anti-tissue factor antibody drug
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
SG11202011633SA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Psma binding agents and uses thereof
|
|
WO2019231870A1
(en)
|
2018-05-31 |
2019-12-05 |
Merck Sharp & Dohme Corp. |
Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
EP3810109B1
(en)
|
2018-05-31 |
2024-08-07 |
Peloton Therapeutics, Inc. |
Compounds and compositions for inhibiting cd73
|
|
ES2973518T3
(es)
|
2018-06-03 |
2024-06-20 |
Lamkap Bio Beta Ag |
Anticuerpos biespecíficos contra CEACAM5 y CD47
|
|
WO2019242505A1
(zh)
|
2018-06-17 |
2019-12-26 |
上海健信生物医药科技有限公司 |
靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
|
|
DK3807316T3
(da)
|
2018-06-18 |
2024-07-29 |
Innate Pharma |
Sammensætninger og fremgangsmåder til behandling af cancer
|
|
US11274111B2
(en)
|
2018-06-20 |
2022-03-15 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
EP3819313A4
(en)
|
2018-07-03 |
2021-09-01 |
L&L Biopharma Co., Ltd. |
BISPECIFIC ANTIBODY AND USE OF IT
|
|
JP2021528988A
(ja)
*
|
2018-07-04 |
2021-10-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
|
|
JP2021529814A
(ja)
|
2018-07-09 |
2021-11-04 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
化学化合物
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020014543A2
(en)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
US20210301020A1
(en)
|
2018-07-24 |
2021-09-30 |
Amgen Inc. |
Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
|
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
|
CN113164538B
(zh)
*
|
2018-09-10 |
2025-03-04 |
上海锦斯生物技术有限公司 |
修饰的溶瘤病毒、其组合物和用途
|
|
CA3113301A1
(en)
*
|
2018-09-11 |
2020-03-19 |
iTeos Belgium SA |
Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
|
|
ES3014591T3
(en)
*
|
2018-09-11 |
2025-04-23 |
Curis Inc |
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
|
|
EP3849606A4
(en)
|
2018-09-13 |
2022-06-29 |
Merck Sharp & Dohme Corp. |
Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
|
|
BR112021004935A2
(pt)
|
2018-09-26 |
2021-06-01 |
Merck Patent Gmbh |
combinação de antagonista de pd-1, inibidor de atr e agente de platinação para tratamento de câncer
|
|
WO2020081381A1
(en)
|
2018-10-17 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Novel arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
IL308722B2
(en)
|
2018-10-17 |
2025-01-01 |
Biolinerx Ltd |
Treatment of metastatic pancreatic adenocarcinoma
|
|
JP2022513374A
(ja)
|
2018-10-22 |
2022-02-07 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
投薬
|
|
MX2021004906A
(es)
|
2018-10-29 |
2021-09-10 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
US12257286B2
(en)
|
2018-10-31 |
2025-03-25 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
EP3873500A4
(en)
|
2018-10-31 |
2023-01-11 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
US12091405B2
(en)
|
2018-11-01 |
2024-09-17 |
Merck Sharp & Dohme Llc |
Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
WO2020096871A1
(en)
|
2018-11-06 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
EP3880705A1
(en)
*
|
2018-11-14 |
2021-09-22 |
Bayer Aktiengesellschaft |
Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
|
|
SG11202104923YA
(en)
|
2018-11-16 |
2021-06-29 |
Arqule Inc |
Pharmaceutical combination for treatment of cancer
|
|
WO2020106560A1
(en)
|
2018-11-20 |
2020-05-28 |
Merck Sharp & Dohme Corp. |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
CN113015530A
(zh)
|
2018-11-20 |
2021-06-22 |
默沙东公司 |
取代的氨基三唑并嘧啶和氨基三唑并吡嗪腺苷受体拮抗剂、药物组合物及其用途
|
|
WO2020109328A1
(en)
|
2018-11-26 |
2020-06-04 |
Debiopharm International S.A. |
Combination treatment of hiv infections
|
|
WO2020112581A1
(en)
|
2018-11-28 |
2020-06-04 |
Merck Sharp & Dohme Corp. |
Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
|
|
JOP20210117A1
(ar)
|
2018-11-30 |
2023-01-30 |
Merck Sharp & Dohme |
مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
|
|
AU2019390729B2
(en)
|
2018-11-30 |
2022-08-11 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in HIV therapy
|
|
SG11202104331YA
(en)
|
2018-12-11 |
2021-05-28 |
Theravance Biopharma R&D Ip Llc |
Naphthyridine and quinoline derivatives useful as alk5 inhibitors
|
|
US12240867B2
(en)
|
2018-12-18 |
2025-03-04 |
Merck Sharp & Dohme Llc |
Arginase inhibitors and methods of use
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
|
CN113329792B
(zh)
|
2019-02-15 |
2024-06-28 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
|
CN109879855B
(zh)
*
|
2019-03-26 |
2021-01-05 |
中国医学科学院医药生物技术研究所 |
靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用
|
|
WO2020205688A1
(en)
|
2019-04-04 |
2020-10-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
BR112021020532A2
(pt)
|
2019-04-19 |
2022-03-15 |
Janssen Biotech Inc |
Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
|
|
BR112021021224A2
(pt)
|
2019-04-23 |
2021-12-21 |
Innate Pharma |
Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
|
|
CN114391015A
(zh)
|
2019-05-16 |
2022-04-22 |
斯汀塞拉股份有限公司 |
苯并[b][1,8]萘啶乙酸衍生物和使用方法
|
|
JP2022533390A
(ja)
|
2019-05-16 |
2022-07-22 |
スティングセラ インコーポレイテッド |
オキソアクリジニル酢酸誘導体および使用方法
|
|
EP3976090A1
(en)
|
2019-05-24 |
2022-04-06 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
WO2020260547A1
(en)
|
2019-06-27 |
2020-12-30 |
Rigontec Gmbh |
Design method for optimized rig-i ligands
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
US12325749B2
(en)
|
2019-07-19 |
2025-06-10 |
Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. |
Anti-PD-L1 antibody and use thereof
|
|
US12036204B2
(en)
|
2019-07-26 |
2024-07-16 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
TW202120500A
(zh)
|
2019-08-02 |
2021-06-01 |
美商梅爾莎納醫療公司 |
干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
PE20221045A1
(es)
|
2019-09-18 |
2022-06-22 |
Lamkap Bio Alpha AG |
Anticuerpos biespecificos contra ceacam5 y cd3
|
|
WO2021053207A1
(en)
|
2019-09-20 |
2021-03-25 |
Transgene |
Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody
|
|
BR112022005787A2
(pt)
|
2019-09-27 |
2022-06-21 |
Glaxosmithkline Ip Dev Ltd |
Proteínas de ligação a antígeno
|
|
CN114829357A
(zh)
|
2019-10-28 |
2022-07-29 |
中国科学院上海药物研究所 |
五元杂环氧代羧酸类化合物及其医药用途
|
|
TW202137984A
(zh)
|
2019-10-29 |
2021-10-16 |
日商衛材R&D企管股份有限公司 |
用於治療癌症之PD-1拮抗劑、VEGFR/FGFR/RET酪胺酸激酶抑制劑及CBP/β-連環蛋白抑制劑之組合
|
|
IL293084A
(en)
|
2019-11-22 |
2022-07-01 |
Theravance Biopharma R& D Ip Llc |
Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
EP4069683A1
(en)
|
2019-12-06 |
2022-10-12 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
US20220396577A1
(en)
|
2019-12-17 |
2022-12-15 |
Merck Sharp & Dohme Llc |
Novel substituted 1,3-8-triazaspiro[4,5] decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
|
|
CN114981265B
(zh)
|
2019-12-18 |
2025-01-03 |
Ctxt私人有限公司 |
化合物
|
|
AU2020406350A1
(en)
|
2019-12-20 |
2022-08-11 |
Novartis Ag |
Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
WO2021141751A1
(en)
|
2020-01-07 |
2021-07-15 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
JP2023519673A
(ja)
|
2020-03-31 |
2023-05-12 |
セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー |
置換ピリミジンおよび使用方法
|
|
BR122022020762A2
(pt)
|
2020-04-02 |
2023-04-11 |
Mersana Therapeutics, Inc |
Conjugados de anticorpo-fármaco compreendendo agonistas de sting, seu uso e composição
|
|
JP2023521465A
(ja)
|
2020-04-14 |
2023-05-24 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ＩＣＯＳ抗体とＰＤ－Ｌ１抗体ＴＧＦ－β－受容体融合タンパク質とに基づく癌の併用治療
|
|
TW202206100A
(zh)
|
2020-04-27 |
2022-02-16 |
美商西健公司 |
癌症之治療
|
|
PE20230680A1
(es)
|
2020-05-06 |
2023-04-21 |
Merck Sharp And Dohme Llc |
Inhibidores de il4i1 y metodos de uso
|
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
|
US20210387983A1
(en)
|
2020-06-10 |
2021-12-16 |
Theravance Biopharma R&D Ip, Llc |
Crystalline alk5 inhibitors and uses thereof
|
|
BR112022025856A2
(pt)
|
2020-06-19 |
2023-01-10 |
Hoffmann La Roche |
Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção
|
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
WO2022003554A1
(en)
|
2020-07-01 |
2022-01-06 |
Pfizer Inc. |
Biomarkers for pd-1 axis binding antagonist therapy
|
|
CA3182579A1
(en)
|
2020-07-07 |
2022-01-13 |
Ugur Sahin |
Therapeutic rna for hpv-positive cancer
|
|
IL299789A
(en)
*
|
2020-07-13 |
2023-03-01 |
Verastem Inc |
Combinations of MEK/RAF suppressor and anti-1-PD antibody for cancer therapy
|
|
EP4208482A1
(en)
|
2020-09-02 |
2023-07-12 |
Pharmabcine Inc. |
Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
|
|
KR20230121772A
(ko)
|
2020-12-18 |
2023-08-21 |
람카프 바이오 베타 엘티디. |
Ceacam5 및 cd47에 대한 이중특이적 항체
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
CA3210246A1
(en)
|
2021-01-28 |
2022-08-04 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
IL304891A
(en)
|
2021-02-02 |
2023-10-01 |
Servier Lab |
Selective Protech BCL-XL compounds and methods of use
|
|
AU2022230795B2
(en)
|
2021-03-02 |
2025-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
|
JP2024511373A
(ja)
|
2021-03-18 |
2024-03-13 |
ノバルティス アーゲー |
がんのためのバイオマーカーおよびその使用
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
JP2024511831A
(ja)
|
2021-03-31 |
2024-03-15 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質およびそれらの組み合わせ
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AU2022254104A1
(en)
|
2021-04-08 |
2023-10-26 |
Nurix Therapeutics, Inc. |
Combination therapies with cbl-b inhibitor compounds
|
|
US20240182571A1
(en)
|
2021-04-09 |
2024-06-06 |
Ose Immunotherapeutics |
New scaffold for bifunctional molecules with improved properties
|
|
WO2022214652A1
(en)
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
WO2022227015A1
(en)
|
2021-04-30 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Il4i1 inhibitors and methods of use
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
EP4351595A1
(en)
|
2021-06-07 |
2024-04-17 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
MX2024000674A
(es)
|
2021-07-13 |
2024-02-07 |
BioNTech SE |
Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
|
|
US20250122285A1
(en)
*
|
2021-07-28 |
2025-04-17 |
Anwita Biosciences, Inc. |
Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications
|
|
EP4377348A1
(en)
|
2021-07-30 |
2024-06-05 |
Seagen Inc. |
Treatment for cancer
|
|
WO2023039583A1
(en)
*
|
2021-09-10 |
2023-03-16 |
Trustees Of Tufts College |
Anti-pd-1 immunoglobulin polypeptides and uses thereof
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
US20240117030A1
(en)
|
2022-03-03 |
2024-04-11 |
Pfizer Inc. |
Multispecific antibodies and uses thereof
|
|
US20250228938A1
(en)
*
|
2022-03-08 |
2025-07-17 |
Whitehead Institute For Biomedical Research |
The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
|
|
IL317103A
(en)
|
2022-05-20 |
2025-01-01 |
Novartis Ag |
Antibody-drug conjugates of MET inhibitor BCL-XL and methods of using them
|
|
EP4525925A1
(en)
|
2022-05-20 |
2025-03-26 |
Novartis AG |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
US20250230256A1
(en)
|
2022-06-16 |
2025-07-17 |
Lamkap Bio Beta Ltd |
Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
|
|
CN120302979A
(zh)
|
2022-12-01 |
2025-07-11 |
生物技术公司 |
针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
|
|
IL321098A
(en)
|
2022-12-14 |
2025-07-01 |
Astellas Pharma Europe Bv |
Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
|
|
WO2024140919A1
(zh)
*
|
2022-12-29 |
2024-07-04 |
南京圣和药业股份有限公司 |
抗crtam/抗pd-l1抗体及其应用
|
|
KR20250154511A
(ko)
|
2023-03-07 |
2025-10-28 |
포토큐어 에이에스에이 |
방광암 치료
|
|
AU2024234194A1
(en)
|
2023-03-10 |
2025-08-07 |
Novartis Ag |
Panras inhibitor antibody-drug conjugates and methods of use thereof
|
|
TW202502311A
(zh)
|
2023-03-29 |
2025-01-16 |
美商默沙東有限責任公司 |
Il4i1抑制劑及其使用方法
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
WO2025034702A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Rmc-6291 for use in the treatment of ras protein-related disease or disorder
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025080946A2
(en)
|
2023-10-12 |
2025-04-17 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025096843A1
(en)
|
2023-11-03 |
2025-05-08 |
Amgen Inc. |
Bispecific molecules
|
|
WO2025111450A1
(en)
|
2023-11-22 |
2025-05-30 |
Les Laboratoires Servier |
Anti-cd74 antibody-drug conjugates and methods of use thereof
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025213154A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
|
|
WO2025215536A1
(en)
|
2024-04-10 |
2025-10-16 |
Novartis Ag |
Macrocyclic panras inhibitors for the treatment of cancer
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|